Evidence map›Paper›PMID 28624931›Full record

ReviewClinical rheumatology2017

Familial Mediterranean fever, review of the literature.

Mansour Alghamdi

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Clinical rheumatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05488561 (Clinical and Molecular Evaluation of Childern With Familial Meditterranean Fever and Their Siblings), which is not on this map. Cited by 87 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed, 1 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05488561 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Clinical and Molecular Evaluation of Childern With Familial Meditterranean Fever and Their Siblings

TypeinterventionalSponsorSohag UniversityRan2022 to 2023Enrolled50ConditionsFamilial Mediterranean FeverArmsCBC with differential ,ESR ,CRP, Amyloid level , FMF gene
3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 1 synthesis or guideline pooled it, 209 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Identification of pathogenicJournal of rheumatic diseases · 2025
    Article
  11. Article
  12. Article
  13. Familial Mediterranean fever with sigmoid colon stricture.Clinical journal of gastroenterology · 2025
    Article
  14. The Role ofInternational journal of molecular sciences · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Mansour AlghamdiMinistry of Health, King Fahd Hospital, Al Baha, Saudi Arabia. mmalgh@hotmail.com.ORCID http://orcid.org/0000-0001-7938-3523
Ministry of Health · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Familial Mediterranean fever (FMF) is the most common monogenic periodic fever syndrome and characterized by recurrent episodes of fever, serositis, arthritis, dermal manifestations, and long-term renal complications. The MEFV gene was described in 1997 as the gene responsible for FMF and is inherited in autosomal recessive manner. It encodes mutated protein pyrin, an important player in the innate immune system and the component of inflammasome which leads to exaggerated inflammatory response through uncontrolled production of interleukin-1. The recent progress in molecular genetics and understanding of pathogenesis showed a more complicated picture of FMF inheritance, penetrance, and pathogenesis. The pathogenesis is not completely understood although the gene responsible for FMF has been identified. Whether the pyrin mutation effect in FMF is due to a loss of function or a gain of function is still controversial. The diagnosis is mainly clinical and the genetic testing is indicated to support it. Colchicine remains the mainstay of treatment of FMF since 1972. It decreases the attacks, improves quality of life, and prevents amyloidosis. The recent advances in genetic testing and molecular studies has led to the development of new therapies of interleukin-1 inhibitors; anakinra, canakinumab, and rilonacept.

Indexed as

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedColchicineFamilial Mediterranean FeverHumansInterleukin 1 Receptor Antagonist ProteinMutationPyrinReceptors, Interleukin-1 Type IRecombinant Fusion ProteinsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedcanakinumabColchicineInterleukin 1 Receptor Antagonist ProteinPyrinReceptors, Interleukin-1 Type IRecombinant Fusion ProteinsrilonaceptAnakinraCanakinumabColchicineDiagnosisFamilial Mediterranean feverGeneticsInterleukin-1 inhibitorsManagementPathogenesisRilonacept

Identifiers

PMID28624931
OpenAlexW2626021281

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.